SynthesisAmerican journal of men's health
Clinical Efficacy and Safety of Botulinum Toxin A Injection into the Bulbospongiosus Muscle for Treating Lifelong Premature Ejaculation: A Systematic Review and Meta-Analysis.
Synthesis in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Botulinum toxin a combined with penile traction therapy for the treatment of penile retraction: a retrospective single-arm pilot study.International journal of impotence research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin A (BoNT/A) injections into the bulbospongiosus muscle have emerged as a novel treatment for lifelong premature ejaculation (PE), though efficacy remains controversial. This study evaluates BoNT/A's efficacy and safety through a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, and ISRCTN registry. We included randomized controlled trials, prospective, and retrospective studies, focusing on intravaginal ejaculation latency time (IELT) and adverse events. Four studies (three meta-analyzed) involving 263 patients were analyzed. BoNT/A increased IELT by 37.87 s at 1 month (MD, 37.87; 95% CI, -2.86 to 78.59;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.